Innovus Pharmaceuticals Inc (INNV) Stock Rating Lowered by Zacks Investment Research
Innovus Pharmaceuticals Inc (NASDAQ:INNV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Shares of Innovus Pharmaceuticals (NASDAQ INNV) opened at 0.1085 on Friday. The stock has a 50 day moving average of $0.11 and a 200 day moving average of $0.12. The company’s market cap is $16.42 million. Innovus Pharmaceuticals has a 1-year low of $0.08 and a 1-year high of $0.39.
Innovus Pharmaceuticals (NASDAQ:INNV) last released its quarterly earnings data on Monday, August 14th. The company reported ($0.01) EPS for the quarter. Innovus Pharmaceuticals had a negative net margin of 116.92% and a negative return on equity of 493.09%. The business had revenue of $2.04 million for the quarter. Analysts predict that Innovus Pharmaceuticals will post ($0.07) EPS for the current year.
Innovus Pharmaceuticals Company Profile
Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.
Receive News & Stock Ratings for Innovus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.